GlaxoSmithKline Market Cap 2006-2019 | GSK

GlaxoSmithKline market cap history and chart from 2006 to 2019. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of diluted shares outstanding. GlaxoSmithKline market cap as of May 24, 2019 is $99.67B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $99.670B $41.140B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $372.521B 16.89
Pfizer (PFE) United States $249.723B 13.62
Merck (MRK) United States $218.850B 18.00
Novartis AG (NVS) Switzerland $202.171B 17.47
Novo Nordisk (NVO) Denmark $118.731B 19.75
AbbVie (ABBV) United States $118.355B 9.79
Eli Lilly (LLY) United States $113.383B 21.04
Sanofi (SNY) France $105.545B 13.01
AstraZeneca (AZN) United Kingdom $98.834B 11.38
Bristol-Myers Squibb (BMY) United States $76.567B 11.31